These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12594449)

  • 1. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 2. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic choices in the management of acute congestive heart failure.
    Young JB
    Rev Cardiovasc Med; 2001; 2 Suppl 2():S19-24. PubMed ID: 12439358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging drug therapies for the management of acute heart failure.
    Krum H; Liew D
    Intern Med J; 2003 Nov; 33(11):515-20. PubMed ID: 14656255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing outcomes in the patient with acute decompensated heart failure.
    Mehra MR
    Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
    Jain P; Massie BM; Gattis WA; Klein L; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S3-17. PubMed ID: 12594447
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview of emerging pharmacologic agents for acute heart failure syndromes.
    De Luca L; Mebazaa A; Filippatos G; Parissis JT; Böhm M; Voors AA; Nieminen M; Zannad F; Rhodes A; El-Banayosy A; Dickstein K; Gheorghiade M
    Eur J Heart Fail; 2008 Feb; 10(2):201-13. PubMed ID: 18279775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lost decade of nesiritide.
    Topol EJ
    N Engl J Med; 2011 Jul; 365(1):81-2. PubMed ID: 21732841
    [No Abstract]   [Full Text] [Related]  

  • 10. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
    Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM
    Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
    Graham CA
    Emerg Med Australas; 2004 Feb; 16(1):47-54. PubMed ID: 15239755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
    Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nesiritide--not verified.
    Schreiner G
    N Engl J Med; 2005 Oct; 353(14):1525-7; author reply 1525-7. PubMed ID: 16211709
    [No Abstract]   [Full Text] [Related]  

  • 14. B-type natriuretic peptide: from bench to bedside.
    Adams KF; Mathur VS; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S34-46. PubMed ID: 12594450
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
    Kivikko M; Sundberg S; Karlsson MO; Pohjanjousi P; Colucci WS
    Scand Cardiovasc J; 2011 Apr; 45(2):86-90. PubMed ID: 21133820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
    Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute decompensated heart failure: treatment, controversy, and future directions.
    Munger MA
    Pharmacotherapy; 2006 Aug; 26(8 Pt 2):131S-138S. PubMed ID: 16863479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical review and recommendations for nesiritide use in the emergency department.
    Collins SP; Hinckley WR; Storrow AB
    J Emerg Med; 2005 Oct; 29(3):317-29. PubMed ID: 16183453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.